{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:26:43Z","timestamp":1782444403647,"version":"3.54.5"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR002553"],"award-info":[{"award-number":["UL1TR002553"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["3P01AI129859"],"award-info":[{"award-number":["3P01AI129859"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2T32AI052077-16A1"],"award-info":[{"award-number":["2T32AI052077-16A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biostatistics, Epidemiology and Research Design Methods"},{"name":"Translating Duke Health Initiative"},{"name":"Duke Center for Human Systems Immunology"},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius Foundation","doi-asserted-by":"publisher","award":["2016-A126"],"award-info":[{"award-number":["2016-A126"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medearis CMV Scholar Award"},{"DOI":"10.13039\/100006512","name":"Duke University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006512","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human cytomegalovirus (HCMV) is the most common infectious complication of organ transplantation and cause of birth defects worldwide. There are limited therapeutic options and no licensed vaccine to prevent HCMV infection or disease. To inform development of HCMV antibody-based interventions, a previous study identified individuals with potent and broad plasma HCMV-neutralizing activity, termed elite neutralizers (ENs), from a cohort of HCMV-seropositive (SP) blood donors. However, the specificities and functions of plasma antibodies associated with EN status remained undefined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We sought to determine the plasma antibody specificities, breadth, and Fc-mediated antibody effector functions associated with the most potent HCMV-neutralizing responses in plasma from ENs (n = 25) relative to that from SP donors (n = 19). We measured antibody binding against various HCMV strains and glycoprotein targets and evaluated Fc-mediated effector functions, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We demonstrate that ENs have elevated immunoglobulin G binding responses against multiple viral glycoproteins, relative to SP donors. Our study also revealed potent HCMV-specific antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis activity of plasma from ENs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We conclude that antibody responses against multiple glycoprotein specificities may be needed to achieve potent plasma neutralization and that potently HCMV elite-neutralizing plasma antibodies can also mediate polyfunctional responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiac341","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T22:47:57Z","timestamp":1660603677000},"page":"1667-1677","source":"Crossref","is-referenced-by-count":11,"title":["Characterization of Plasma Immunoglobulin G Responses in Elite Neutralizers of Human Cytomegalovirus"],"prefix":"10.1093","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-6198","authenticated-orcid":false,"given":"Melissa J","family":"Harnois","sequence":"first","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina , USA"},{"name":"Department of Immunology, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dennis","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"St\u00f6hr","sequence":"additional","affiliation":[{"name":"Institute for Virology, Ulm University Medical Center , Ulm, Baden-W\u00fcrttemberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M","family":"Valencia","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Rodgers","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina , USA"},{"name":"Department of Surgery, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor C","family":"Semmes","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina , USA"},{"name":"Medical Scientist Training Program, Department of Molecular Genetics and Microbiology, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen S","family":"Webster","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A","family":"Jenks","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina , USA"},{"name":"Medical Scientist Training Program, Department of Molecular Genetics and Microbiology, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Barfield","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Duke University School of Medicine , Durham, North Carolina , USA"},{"name":"Center for Human Systems Immunology, Duke University Medical Center , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Pollara","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina , USA"},{"name":"Department of Surgery, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliburn","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Duke University School of Medicine , Durham, North Carolina , USA"},{"name":"Center for Human Systems Immunology, Duke University Medical Center , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sinzger","sequence":"additional","affiliation":[{"name":"Institute for Virology, Ulm University Medical Center , Ulm, Baden-W\u00fcrttemberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallie R","family":"Permar","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, North Carolina , USA"},{"name":"Department of Pediatrics, Weill Cornell Medicine , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"2023060109464599200_jiac341-B1","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1099\/vir.0.81891-0","article-title":"Latency and reactivation of human cytomegalovirus","volume":"87","author":"Sinclair","year":"2006","journal-title":"J Gen Virol"},{"key":"2023060109464599200_jiac341-B2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev Med Virol"},{"key":"2023060109464599200_jiac341-B3","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev Med Virol"},{"key":"2023060109464599200_jiac341-B4","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1128\/AAC.00523-15","article-title":"Phase 1 randomized, double-blind, placebo-controlled study of RG7667, an anticytomegalovirus combination monoclonal antibody therapy, in healthy adults","volume":"59","author":"Ishida","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023060109464599200_jiac341-B5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/jcp.54.2.84","article-title":"Investigation of CMV disease in immunocompromised patients","volume":"54","author":"Emery","year":"2001","journal-title":"J Clin Pathol"},{"key":"2023060109464599200_jiac341-B6","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"2023060109464599200_jiac341-B7","doi-asserted-by":"crossref","first-page":"e59863","DOI":"10.1371\/journal.pone.0059863","article-title":"Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH\/gL\/pUL128-130-131 complex during primary infection","volume":"8","author":"Lilleri","year":"2013","journal-title":"PLoS One"},{"key":"2023060109464599200_jiac341-B8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jinf.2016.02.008","article-title":"Use of antibodies neutralizing epithelial cell infection to diagnose patients at risk for CMV disease after transplantation","volume":"72","author":"Blanco-Lobo","year":"2016","journal-title":"J Infect"},{"key":"2023060109464599200_jiac341-B9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1126\/science.aat0066","article-title":"Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation","volume":"363","author":"Martins","year":"2019","journal-title":"Science"},{"key":"2023060109464599200_jiac341-B10","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.tim.2020.04.003","article-title":"Role of neutralizing antibodies in CMV infection: implications for new therapeutic approaches","volume":"28","author":"Sandonis","year":"2020","journal-title":"Trends Microbiol"},{"key":"2023060109464599200_jiac341-B11","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023060109464599200_jiac341-B12","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"115","author":"Baraniak","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023060109464599200_jiac341-B13","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/v13061106","article-title":"Common polymorphisms in the glycoproteins of human cytomegalovirus and associated strain-specific immunity","volume":"13","author":"Wang","year":"2021","journal-title":"Viruses"},{"key":"2023060109464599200_jiac341-B14","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/infdis\/jiy102","article-title":"Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: anti-AD2 levels correlate with protection from viremia","volume":"217","author":"Baraniak","year":"2018","journal-title":"J Infect Dis"},{"key":"2023060109464599200_jiac341-B15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3389\/fmicb.2019.01005","article-title":"HCMV envelope glycoprotein diversity demystified","volume":"10","author":"Foglierini","year":"2019","journal-title":"Front Microbiol"},{"key":"2023060109464599200_jiac341-B16","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/JVI.00467-12","article-title":"Antibodies against the gH\/gL\/UL128\/UL130\/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin","volume":"86","author":"Fouts","year":"2012","journal-title":"J Virol"},{"key":"2023060109464599200_jiac341-B17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J Virol"},{"key":"2023060109464599200_jiac341-B18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004524","article-title":"Human cytomegalovirus vaccine based on the envelope gH\/gL pentamer complex","volume":"10","author":"Wussow","year":"2014","journal-title":"PLoS Pathog"},{"key":"2023060109464599200_jiac341-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1005564","article-title":"Human cytomegalovirus gH\/gL forms a stable complex with the fusion protein gB in virions","volume":"12","author":"Vanarsdall","year":"2016","journal-title":"PLoS Pathog"},{"key":"2023060109464599200_jiac341-B20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006281","article-title":"Human cytomegalovirus glycoprotein complex gH\/gL\/gO uses PDGFR-\u03b1 as a key for entry","volume":"13","author":"Wu","year":"2017","journal-title":"PLoS Pathog"},{"key":"2023060109464599200_jiac341-B21","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nmicrobiol.2016.82","article-title":"Platelet-derived growth factor-\u03b1 receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer","volume":"1","author":"Kabanova","year":"2016","journal-title":"Nat Microbiol"},{"key":"2023060109464599200_jiac341-B22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11544","article-title":"Broad and potent neutralization of HIV-1 by a gp41-specific human antibody","volume":"491","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"2023060109464599200_jiac341-B23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.12659\/AOT.898050","article-title":"Functional properties of human cytomegalovirus hyperimmunoglobulin and standard immunoglobulin preparations","volume":"21","author":"Germer","year":"2016","journal-title":"Ann Transplant"},{"key":"2023060109464599200_jiac341-B24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000487302","article-title":"Histological analysis of term placentas from hyperimmune globulin-treated and untreated mothers with primary cytomegalovirus infection","volume":"45","author":"Gabrielli","year":"2019","journal-title":"Fetal Diagn Ther"},{"key":"2023060109464599200_jiac341-B25","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJMoa1310214","article-title":"A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus","volume":"370","author":"Revello","year":"2014","journal-title":"N Engl J Med"},{"key":"2023060109464599200_jiac341-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13052-017-0358-8","article-title":"Congenital cytomegalovirus infection: advances and challenges in diagnosis, prevention and treatment","volume":"43","author":"Marsico","year":"2017","journal-title":"Ital J Pediatr"},{"key":"2023060109464599200_jiac341-B27","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJMoa043337","article-title":"Passive immunization during pregnancy for congenital cytomegalovirus infection","volume":"353","author":"Nigro","year":"2005","journal-title":"N Engl J Med"},{"key":"2023060109464599200_jiac341-B28","article-title":"Crystal structure of the human cytomegalovirus glycoprotein B","volume":"11","author":"Burke","year":"2015","journal-title":"PLoS Pathog"},{"key":"2023060109464599200_jiac341-B29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"2023060109464599200_jiac341-B30","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"2023060109464599200_jiac341-B31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002172","article-title":"B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies","volume":"7","author":"P\u00f6tzsch","year":"2011","journal-title":"PLoS Pathog"},{"key":"2023060109464599200_jiac341-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.abb3611","article-title":"Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB\/MF59 vaccine in humans","volume":"12","author":"Jenks","year":"2020","journal-title":"Sci Transl Med"},{"key":"2023060109464599200_jiac341-B33","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/infdis\/jiy229","article-title":"Identification of elite neutralizers with broad and potent neutralizing activity against human cytomegalovirus (HCMV) in a population of HCMV-seropositive blood donors","volume":"218","author":"Falk","year":"2018","journal-title":"J Infect Dis"},{"key":"2023060109464599200_jiac341-B34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/trf.13906","article-title":"A two-step screening approach for the identification of blood donors with highly and broadly neutralizing capacities against human cytomegalovirus","volume":"57","author":"Falk","year":"2017","journal-title":"Transfusion"},{"key":"2023060109464599200_jiac341-B35","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/infdis\/jiw487","article-title":"Maternal antibody responses and nonprimary congenital cytomegalovirus infection of HIV-1-exposed infants","volume":"214","author":"Bialas","year":"2016","journal-title":"J Infect Dis"},{"key":"2023060109464599200_jiac341-B36","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jiz192","article-title":"Humoral immune correlates for prevention of postnatal cytomegalovirus acquisition","volume":"220","author":"Saccoccio","year":"2018","journal-title":"J Infect Dis"},{"key":"2023060109464599200_jiac341-B37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-1759(03)00265-5","article-title":"Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation","volume":"281","author":"Betts","year":"2003","journal-title":"J Immunol Methods"},{"key":"2023060109464599200_jiac341-B38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","article-title":"CD107a as a functional marker for the identification of natural killer cell activity","volume":"294","author":"Alter","year":"2004","journal-title":"J Immunol Methods"},{"key":"2023060109464599200_jiac341-B39","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.virol.2020.07.009","article-title":"Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection","volume":"548","author":"Goodwin","year":"2020","journal-title":"Virology"},{"key":"2023060109464599200_jiac341-B40","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2307\/1924766","article-title":"The uses of Tobit analysis","volume":"62","author":"McDonald","year":"1980","journal-title":"Rev Econ Stat"},{"key":"2023060109464599200_jiac341-B41","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-77318-6","volume-title":"Applied econometrics with R","author":"Kleiber","year":"2008","edition":"1st ed"},{"key":"2023060109464599200_jiac341-B42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2023060109464599200_jiac341-B43","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"2023060109464599200_jiac341-B44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/421496","article-title":"Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients","volume":"39","author":"Coaquette","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2023060109464599200_jiac341-B45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213409","article-title":"Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens","volume":"14","author":"Mesa","year":"2019","journal-title":"PLoS One"},{"key":"2023060109464599200_jiac341-B46","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1099\/0022-1317-73-9-2375","article-title":"Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies","volume":"73","author":"Meyer","year":"1992","journal-title":"J Gen Virol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiac341\/45612995\/jiac341.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/9\/1667\/50499149\/jiac341.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/9\/1667\/50499149\/jiac341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T16:08:48Z","timestamp":1727798928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/9\/1667\/6667625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,8,16]]},"published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac341","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.06.06.22275103","asserted-by":"object"}]},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,8,16]]}}}